A5047442555- Schizophrenia research and treatment
- Bipolar Disorder and Treatment
- Electroconvulsive Therapy Studies
- Tryptophan and brain disorders
- Treatment of Major Depression
- Mental Health and Psychiatry
- Smoking Behavior and Cessation
- Child and Adolescent Psychosocial and Emotional Development
- Parkinson's Disease and Spinal Disorders
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Mental Health Treatment and Access
- Pharmacological Effects and Toxicity Studies
- COVID-19 and Mental Health
- Electrolyte and hormonal disorders
- Hemispheric Asymmetry in Neuroscience
- Psychosomatic Disorders and Their Treatments
- Pharmaceutical Practices and Patient Outcomes
- Gastroesophageal reflux and treatments
- Nicotinic Acetylcholine Receptors Study
- Diabetes and associated disorders
- Healthcare Decision-Making and Restraints
- Mental Health Research Topics
- Gastrointestinal motility and disorders
- Diabetes Treatment and Management
- Epilepsy research and treatment
Psychiatric Medical Center
2023-2025
University of Pittsburgh
2016-2025
University of Pittsburgh Medical Center
2010-2025
VA San Diego Healthcare System
2025
Behavioral Health Network
2025
Emory University
2024
Western Pennsylvania Hospital
2004-2024
Allegheny County
2023
Allegheny County Department of Human Services
2023
Pittsburg State University
2018
The primary intent of this study was to compare the efficacy and safety olanzapine placebo in treatment acute mania.The design involved a random-assignment, double-blind, placebo-controlled parallel group 3 weeks' duration. After 2- 4-day screening period, qualified patients were assigned either (N = 70) or 69). Patients began double-blind therapy with olanzapine, 10 mg, given once per day. first day treatment, daily dose could be adjusted upward downward, as clinically indicated, by one...
<h3>Background</h3> A 6-week double-blind, randomized, placebo-controlled trial was conducted to determine the efficacy of combined therapy with olanzapine and either valproate or lithium compared alone in treating acute manic mixed bipolar episodes. <h3>Methods</h3> The primary objective evaluate (5-20 mg/d) vs placebo when added ongoing mood-stabilizer as measured by reductions Young Mania Rating Scale (YMRS) scores. Patients disorder (n = 344), episode, who were inadequately responsive...
Few controlled studies have examined the use of atypical antipsychotic drugs for prevention relapse in patients with bipolar I disorder. Aims To evaluate whether olanzapine plus either lithium or valproate reduces rate relapse, compared alone.Patients achieving syndromic remission after 6 weeks'treatment (0.6-1.2 mmol/l) (50-125 microg/ml) received 5-20 mg/day (combination therapy) placebo (monotherapy), and were followed a double-masked trial 18 months.The treatment difference time to into...
Article AbstractObjective: Cognitive impairments contribute significantly to inadequate functional recovery following illness episodes in bipolar disorder, yet data on treatment interventions are sparse. We assessed the cognitive effects of a standardized extract medicinal herb Withania somnifera (WSE) disorder.Method: Sixty euthymic subjects with DSM-IV disorder were enrolled an 8-week, double-blind, placebo-controlled, randomized study WSE (500 mg/d) as procognitive agent added...
Objective: Therapeutic options are limited for treatment-resistant bipolar depression (TRBD). Insulin resistance (IR) confers increased risk TRBD. We investigated metformin, an insulin sensitizer, to reverse IR and improve clinical outcomes in Methods: Using a random-assignment (1:1), intent-to-treat, 2-site, quadruple-masked, parallel-group (metformin 2,000 mg/d or placebo) trial design, patients with DSM-5 disorder (BD) type I II received study medication 26 weeks (February 2016 October...
Clozapine has been reported to be effective in diminishing violence toward others psychotic patients. This article describes the impact of clozapine on severe self-mutilation among patients with dual diagnoses borderline personality disorder and persistent psychoses.Seven subjects known authors were selected for careful chart audits. These had admitted 2 state psychiatric hospitals owing and/or subsequently treated clozapine. A mirror-image design anchored start date treatment extending...
Utilizing data from a previously characterized registry of subjects with bipolar illness, the authors examined age at onset first illness episode in cohorts born 1900 through 1939 and 1940 1959.Demographic clinical characteristics full disorder diagnostically validated voluntary (N=1,218) were reviewed subjected to statistical analyses.The median was lower by 4.5 years during or after (median age=19 years), compared before age=23.5 years). The proportion presenting prepubertal significantly...
Article Abstract Objective: Virtually no clinical trials for smoking cessation have been undertaken in bipolar disorder. Varenicline has shown efficacy cessation, but warnings about neuropsychiatric adverse events issued. We assessed the and safety of varenicline euthymic subjects motivated to quit smoking. Method: Clinically stable adult patients with DSM-IV disorder (n = 60) who smoked ≥ 10 cigarettes per day were randomized a 3-month, double-blind, placebo-controlled trial 3-month...
To determine if adjunctive treatment with a standardized extract of Withania somnifera (WSE), known anti-inflammatory and immunomodulating properties, improves psychopathology stress in patients schizophrenia or schizoaffective disorder (DSM-IV-TR).Patients experiencing an exacerbation symptoms were assigned to WSE (1,000 mg/d) placebo for 12 weeks, added their antipsychotic medication, random-assignment, double-blind, placebo-controlled study conducted from April 2013 July 2016. Primary...
Insulin resistance is common in bipolar disorders and may be a driver of both chronic depressive symptoms treatment nonresponse. Research suggests that insulin associated with certain structural brain changes, including blood barrier leakage, lead to neuroprogression the illness. Importantly, not detected through use conventional laboratory tests, i.e., fasting glucose glycosylated hemoglobin, but by measuring same draw. Reversal sensitizers provide path out resistant depression (TRBD). In...
Clozapine is the only medication approved for treatment-resistant schizophrenia. toxicity associated with COVID-19 infection could be amplified by concomitant nirmatrelvir/ritonavir. Knowledge gaps among clinicians and patients led to patient safety concerns implementation of a quality improvement (QI) project focused on rapid education dissemination. This QI clinicians, patients, caregivers. Steps included clinician at system, regional, national levels patient/caregiver system regional...
Summary Topiramate is an antiepileptic agent, which being investigated as a mood-stabilizer. Three obese individuals with DSM-IV bipolar I disorder and type II diabetes mellitus received topiramate treatment in combination antipsychotics valproate or carbamazepine. In addition to improved mood stability, these lost between 16 20.5% of their pre-topiramate body weight also achieved significant glycemic control.
Article Abstract Objective: To investigate the efficacy and safety of topiramate versus placebo as adjunctive therapy for outpatient management bipolar I disorder. Method: In this 12-week, randomized, double-blind, placebo-controlled trial, adults with disorder (DSM-IV criteria) experiencing a manic or mixed episode Young Mania Rating Scale (YMRS) score >= 18 while taking therapeutic levels valproate lithium received placebo. Topiramate was titrated from 25 to 400 mg/day over 8 weeks...
Candidate medications for smoking cessation may be screened more efficiently if initial evaluations in humans combine the practical advantages of laboratory studies with clinical validity trials, such as by increasing participants' "quit motivation" during brief testing. We manipulated "intrinsic" quit motivation recruiting smokers who either did intend to soon ("treatment seekers," N = 47) or not ("nonseekers," 93), and "extrinsic" providing reinforcement abstinence ($2/day). All subjects...